A new trading day began on Monday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price down -1.21% from the previous day of trading, before settling in for the closing price of $6.18. RXRX’s price has ranged from $5.89 to $15.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 132.77%. Meanwhile, its annual earnings per share averaged 1.97%. With a float of $221.54 million, this company’s outstanding shares have now reached $226.26 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 22.71%, while institutional ownership is 79.05%. The most recent insider transaction that took place on Nov 13 ’24, was worth 154,800. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $7.74, taking the stock ownership to the 762,656 shares. Before that another transaction happened on Nov 14 ’24, when Company’s Chief Executive Officer sold 20,000 for $7.35, making the entire transaction worth $147,000. This insider now owns 762,656 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 1.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.68 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Compared to the last year’s volume of 5.77 million, its volume of 8.19 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 13.06%. Additionally, its Average True Range was 0.49.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 7.54%, which indicates a significant decrease from 7.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.17% in the past 14 days, which was higher than the 72.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.66, while its 200-day Moving Average is $8.38. Nevertheless, the first resistance level for the watch stands at $6.27 in the near term. At $6.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.63. If the price goes on to break the first support level at $5.91, it is likely to go to the next support level at $5.73. Now, if the price goes above the second support level, the third support stands at $5.55.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 1.56 billion, the company has a total of 281,109K Shares Outstanding. Currently, annual sales are 44,580 K while annual income is -328,070 K. The company’s previous quarter sales were 26,080 K while its latest quarter income was -95,840 K.
